Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual…
Browsing: Clinical Trials
Guoyuan International issued a research report on Essex Bio-Technology on 1 April 2026. Essex posted steady operating performance growth in…
Across the landscape of global biotech companies, the appointment of a senior executive often serves as a “barometer”—offering insights into…
On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its…
CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by…
Essex Bio-Technology Limited (EssexBio or the Company; HKG: 1061) today announces its successful participation in the 41st Asia-Pacific Academy of…
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine OBI Pharma (4174.TWO) announced that it…
PromiCell, Inc. (the Company), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients,…
Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of…
In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies,…
Essex Bio-Technology Limited (Essex or the Group, HKG: 1061) is pleased to announce that a Biologics License Application (BLA) for…
On July 15 2025, to mark the successful secondary listing of China Medical System Holdings Limited (“CMS” or the “Group”)…
Technology Co-Developed by the U.S. Department of Veteran Affairs and Emory University Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the…
Hua Medicine (the Company, HKG: 2552) announced today that the Company presented the latest research results of dorzagliatin, its global…
Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to…
– Offer price of S$0.25 per share is at an attractive premium of 61.3% over the last traded price being…
HighTide Therapeutics, Inc. (HKG: 2511), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic…
HighTide Therapeutics Announces HTD1801 Meets the Primary Endpoints in Two Phase 3 Clinical Trials in Patients with Type 2 Diabetes…
– Data from the proof-of-concept study showed berberine ursodeoxycholate was generally well tolerated and had beneficial therapeutic effect in improving…
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial…